Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ashley Yeo

Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.

As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.

As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.

A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.

These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”

Advertisement
Set Alert for Articles By Ashley Yeo

Latest From Ashley Yeo

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

Clinical Trials Innovation

European Medtech SMEs Are In Denial Over EU MDR And New Clinical Data Needs

The EU Medical Device Regulation (MDR) is front and center for global medtech companies wanting to succeed in the EU in the next decade and beyond. Or at least it should be, but the fear is that smaller players are not ready for its stringent clinical trials regulations and many other key changes it will bring. The potential impact on the medtech ecosystem and the flow of innovation in Europe is becoming a serious concern.

EU Clinical Trials

Medtech Reg Progress In Russia, CIS And Eurasian Union At Operational Level

Various economies of the Commonwealth of Independent States (CIS) and the Eurasian Economic Union (EAEU) are pressing ahead with medtech regulatory changes nationally and/or regionally, which can only be good for the delivery of quality care over the long term. But a question mark still hangs over the official start date of the EAEU medtech regulatory system; a formal postponement may be decided soon.

EAEU Belarus

Brexit Update: UK Medtech Industry Viewpoint, And One Notified Body's Strategy

The case for and against Brexit is only becoming more complex as the months advance toward Brexit Day (March 29, 2019) and the December 2020 end of the UK transition/implementation period. Offering what support it can, UK medical device industry association ABHI held a Brexit information seminar in April. At the gathering, UK notified body BSI revealed the thinking behind its current plans.

EU Brexit

Business As Usual Is Not A Vision For The Future – The Value-Based Shift Is Underway

Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

Healthcare Systems Reimbursement

Reinvigorated German Innovation Strategy May Succeed Where Market Access Tools Have Failed

German medtech manufacturers hope that the fledgling coalition government's promise to give new impetus to the long-running national medtech strategy initiative will help achieve the very innovations that much-vaunted reimbursement fast-tracking mechanisms have failed to yield.

Germany Innovation
See All
Advertisement
UsernamePublicRestriction

Register